Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCyte InternationalTPE:4178 -2.39%7 Altman Z-Score is 1.88 as of Aug. 09, 2026, which is 27% below its 10-year median of 2.59. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review. Among 931 Biotechnology companies, StemCyte International ranks worse than 54.78% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 1.88 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
StemCyte International has a Altman Z-Score of 1.88, indicating it is in Grey Zones. This implies that StemCyte International is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for StemCyte International's Altman Z-Score or its related term are showing as below:
TPE:4178'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.88 Med: 2.59 Max: 2.88
Current: 1.88
During the past 4 years, StemCyte International's highest Altman Z-Score was 2.88. The lowest was 1.88. And the median was 2.59.
StemCyte International (TPE:4178) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
StemCyte International Altman Z-Score Related Terms
StemCyte International Altman Z-Score Historical Data
* Premium members only.
The historical data trend for StemCyte International's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4178 vs VRTX, REGN, RVMD: Altman Z-Score Comparison
For the Biotechnology subindustry, StemCyte International's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCyte International Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCyte International's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where StemCyte International's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
StemCyte International (TPE:4178) has a Altman Z-Score of 1.88 as of Aug. 09, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on StemCyte International and its competitors. This is 27% below median its historical median of 2.59. Over the past decade, StemCyte International's Altman Z-Score has ranged from 1.88 to 2.88. According to the industry distribution chart, StemCyte International ranks #510 out of 931 companies in the Biotechnology industry, placing it in the top 54.8%.
Is StemCyte International's Altman Z-Score too high?
StemCyte International's current Altman Z-Score of 1.88 is 27% below median its 10-year median of 2.59. Over the past 10 years, this metric has ranged from a low of 1.88 to a high of 2.88. The Biotechnology industry median Altman Z-Score is 2.57. StemCyte International's value of 1.88 is 26.8% below this industry median. Based on the distribution chart, StemCyte International ranks #510 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCyte International ranks #510 out of 931 companies for Altman Z-Score. This places StemCyte International in the lower half of its industry. The industry median Altman Z-Score is 2.57. StemCyte International's value of 1.88 is 26.8% below this benchmark. Historically, StemCyte International's own Altman Z-Score has ranged from 1.88 to 2.88 over the past decade. While the company's 10-year median is 2.59 vs. the industry median of 2.57, StemCyte International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.57, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCyte International's current Altman Z-Score of 1.88 is 26.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on StemCyte International and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCyte International's current Altman Z-Score is 1.88, which is 27% below median its own 10-year median of 2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current Altman Z-Score of 1.88. The current Altman Z-Score is 1.88, which is 27% below median its 10-year median of 2.59 and 26.8% below the Biotechnology industry median of 2.57. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current Altman Z-Score is 1.88 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score
Get the complete analysis for TPE:4178
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4178 has been successfully added to your 
